NIS mediates iodide uptake in the female reproductive tract and is a poor prognostic factor in ovarian cancer.

Conclusions: These results provide the basis that will help minimize the impact of therapeutic doses of radioiodide on gonadal function. We also suggest that NIS is a new ovarian cancer marker, opening a door for the use of radioiodide in the diagnosis and treatment of ovarian cancer patients.
PMID: 24708099 [PubMed - as supplied by publisher]

Source: Clinical Breast Cancer - April 7, 2014 Category: Cancer & Oncology Authors: Riesco-Eizaguirre G, Leoni SG, Mendiola M, Estevez-Cebrero MA, Gallego MI, Redondo A, Hardisson D, Santisteban P, De la Vieja A Tags: J Clin Endocrinol Metab Source Type: research